Literature DB >> 15050860

Altered neurotrophin receptor function in the developing prefrontal cortex leads to adult-onset dopaminergic hyperresponsivity and impaired prepulse inhibition of acoustic startle.

N Rajakumar1, L S Leung, J Ma, B Rajakumar, W Rushlow.   

Abstract

BACKGROUND: Survival and differentiation of neurons and the formation and maintenance of synapses in the cerebral cortex may be affected in schizophrenia. Since neurotrophins play an important role in these events, behavioral effects relevant to schizophrenia were investigated in rats that had compromised neurotrophin function during prefrontal cortical development.
METHODS: Neonatal rat pups were injected into the developing prefrontal cortex with a depot preparation of p75 receptor antibody conjugated to saporin. Animals were tested for dopaminergic hyperresponsivity and prepulse inhibition of acoustic startle at 5 or 10 weeks. Neonatal and adult brain sections were examined for morphologic abnormality.
RESULTS: Animals that received neonatal injections of p75 antibody conjugated to saporin showed significantly increased amphetamine-induced locomotion and rearing and impairment of prepulse inhibition of acoustic startle at 10 weeks of age but not at 5 weeks. Examination of adult brain sections revealed apparently normal structure, whereas neonatal brain sections showed apoptotic cells in the developing prefrontal cortex in pups that received p75 antibody conjugated to saporin.
CONCLUSIONS: Compromised p75 neurotrophin receptor function in the developing prefrontal cortex may be associated with the manifestation of adult-onset dopaminergic hyperresponsivity and impaired prepulse inhibition and therefore may be involved in the pathogenesis of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15050860     DOI: 10.1016/j.biopsych.2003.12.015

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  8 in total

1.  Quantitative trait locus analysis identifies rat genomic regions related to amphetamine-induced locomotion and Galpha(i3) levels in nucleus accumbens.

Authors:  Marc N Potenza; Edward S Brodkin; Bao-Zhu Yang; Shari G Birnbaum; Eric J Nestler; Joel Gelernter
Journal:  Neuropsychopharmacology       Date:  2008-01-23       Impact factor: 7.853

2.  Infusions of Nerve Growth Factor Into the Developing Frontal Cortex Leads to Deficits in Behavioral Flexibility and Increased Perseverance.

Authors:  Sagar J Desai; Brian L Allman; Nagalingam Rajakumar
Journal:  Schizophr Bull       Date:  2018-08-20       Impact factor: 9.306

3.  Neurotrophin ligand-receptor systems in somatosensory cortex of adult rat are affected by repeated episodes of ethanol.

Authors:  Marla B Bruns; Michael W Miller
Journal:  Exp Neurol       Date:  2007-01-08       Impact factor: 5.330

Review 4.  Immunological aetiology of major psychiatric disorders: evidence and therapeutic implications.

Authors:  Barbara Sperner-Unterweger
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Contribution of nonprimate animal models in understanding the etiology of schizophrenia.

Authors:  Noah L Lazar; Richard W J Neufeld; Donald P Cain
Journal:  J Psychiatry Neurosci       Date:  2011-07       Impact factor: 6.186

Review 6.  Realistic expectations of prepulse inhibition in translational models for schizophrenia research.

Authors:  Neal R Swerdlow; Martin Weber; Ying Qu; Gregory A Light; David L Braff
Journal:  Psychopharmacology (Berl)       Date:  2008-06-21       Impact factor: 4.530

Review 7.  Dopamine modulation of emotional processing in cortical and subcortical neural circuits: evidence for a final common pathway in schizophrenia?

Authors:  Steven R Laviolette
Journal:  Schizophr Bull       Date:  2007-05-22       Impact factor: 9.306

8.  Injections of NGF into neonatal frontal cortex decrease social interaction as adults: a rat model of schizophrenia.

Authors:  Noah L Lazar; Nagalingam Rajakumar; Donald Peter Cain
Journal:  Schizophr Bull       Date:  2007-05-24       Impact factor: 9.306

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.